



## CME Meeting of EURECA-m and CKD-MBD Working Groups

Makedonia Palace Hotel - Thessaloniki, Greece  
September 13-15, 2018

### Thursday, September 13

16:30 Registrations

17:00-17:15 Welcome and Introduction P. Sarafidis, A. Papagianni

17:15-18:00 Introductory Lecture

18:00-20:00 Session 1

Chairs: I. Boletis, S. Panagoutsos

- Raymond Vanholder Metabolomics approach to cardiovascular risk in CKD
- Jolanta Malyszko Atrial Fibrillation in CKD: an unduring, scarcely focused problem
- Aikaterini Papagianni An update on the role of FGF-23 and Klotho axis in cardiovascular disease
- Marianne Verhaar Regenerative nephrology: a 2018 update

### Friday, September 14

09:00-11:00 Session 2

Chairs: I. Stefanidis, V. Liakopoulos

- Mario Cozzolino Vitamin D rehabilitated for vascular health
- Etienne Cavalier Biomarkers from bone...and beyond!
- Sandro Mazzaferro Inflammation at the crossroad of MBD and cardiovascular disease
- Ziad A. Massy Middle-molecule uremic toxins and outcomes in CKD

11:00-11:30 Coffee-Break

11:30-13:30 Session 3

Chairs: P. Passadakis, A. Karagiannis

- Carmine Zoccali      Neuro-immune links and cardiovascular and renal outcomes in CKD
- Andrzej Więcek      Renal denervation – a chance to slow the CKD progression<sup>-</sup>
- Pantelis Sarafidis      Ambulatory BP, pulse wave analysis and BP variability: potential value in dialysis
- Michael Doumas      Sexual dysfunction in CKD: a circulatory defect or more<sup>-</sup>

13:30-15:00 Lunch Break

15:00-17:00 Session 4

Chairs: D. Vlachakos, TBA

- Francesca Mallamaci      Sleeping disordered breathing in CKD and renal transplantation
- Charles Ferro      Myocardial fibrosis in CKD - from clinic to laboratory and back to the clinic
- Patrick Mark      Stroke and vascular cognitive decline in CKD- what are the targets for intervention<sup>-</sup>
- Apostolos Tsapas      Cardiovascular and renal effects of SGLT-2: a unique opportunity for diabetic patients with CKD<sup>-</sup>

17:00-17:15 Coffee-Break

17:15-19:00 Session 5

Chairs: P. Zebekakis, E. Balaskas

- Jose Valdivielso      Atherosclerosis in CKD: is it really different from the general population<sup>-</sup>
- Robert Ekart      Obesity in patients with CKD: an unappreciated epidemic<sup>-</sup>
- TBA      An update about uric acid in CKD: What should we know and do<sup>-</sup>

## **Saturday, September 15**

09:00-11:00 Session 6

Chairs: D. Goumenos, T. Apostolou,

- Joao Frazão      The Bone-Vessel axis

- Marc Vervloet           Vascular phosphate toxicity revisited
- Mariano Rodriguez    The role of dietary fat in vascular calcification
- Gerard London        Parathyroid hormone as a cardiovascular risk factor in CKD: a reassessment in 2018

11:00-11:30 Coffee-Break

11:30-13:30 Session 7

Chairs: E. Thodis, S. Douma

- Costas Tsioufis        Update on pharmaceutical and interventional treatment of resistant hypertension
- Pablo Ureña-Torres    Effects of antihypertensive treatment on the skeleton
- Alberto Ortiz          Sex differences in CKD incidence and outcomes: beyond sex hormones<sup>2</sup>
- Danilo Fliser          RAAS blockade and hyperkalemia - a cause of concern or not<sup>2</sup>

13:30-13:45 Conclusions and Farewell

P. Sarafidis, D. Goumenos